Gene Delivery to Pig Coronary Arteries from Stents Carrying Antibody-Tethered Adenovirus
- 10 February 2002
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 13 (3) , 443-454
- https://doi.org/10.1089/10430340252792576
Abstract
Deployment of coronary stents to relieve atherosclerotic obstruction has benefitted millions of patients. However, gene therapy to prevent in-stent restenosis, while promising in experimental studies, remains a challenge. Conventional strategies for viral vector administration utilize catheters that deliver infusions of viral suspensions, which result in suboptimal localization and potentially dangerous distal spread of vector. Stent-based gene delivery may circumvent this problem. We hypothesized that site-specific delivery of adenoviral gene vectors from a stent could be achieved through a mechanism involving anti-viral antibody tethering. Stents were formulated with a collagen coating. Anti-adenoviral monoclonal antibodies were covalently bound to the collagen surface. These antibodies enabled tethering of replication defective adenoviruses through highly specific antigen-antibody affinity. We report for the first time successful stent-based gene delivery using antibody-tethered adenovirus encoding green fluorescent protein (GFP), demonstrating efficient and highly localized gene delivery to arterial smooth muscle cells in both cell culture and pig coronary arteries. Overall arterial wall transduction efficiency in pigs was 5.9 +/- 1.1% of total cells. However, neointimal transduction was more than 17% of total cells in this region. Importantly, when specific antibody was used to tether adenovirus, no distal spread of vector was detectable by PCR, in either distal organs, or in the downstream segments of the stented arteries. Control adenovirus stents, with nonspecific antibody plus adenovirus, demonstrated only a few isolated foci of transduction, and poor site-specific transduction with distal spread of vector. We conclude that a vascular stent is a suitable platform for a localizable viral vector delivery system that also prevents systemic spread of vector. Gene delivery using stent-based anti-viral antibody tethering of vectors should be suitable for a wide array of single or multiple therapeutic gene strategies.Keywords
This publication has 23 references indexed in Scilit:
- Focal modification of electrical conduction in the heart by viral gene transferNature Medicine, 2000
- Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six monthsJournal of the American College of Cardiology, 2000
- Gene delivery from a DNA controlled-release stent in porcine coronary arteriesNature Biotechnology, 2000
- FGF2-Targeted Adenovirus Encoding Platelet-Derived Growth Factor-B Enhances de Novo Tissue FormationMolecular Therapy, 2000
- Predictors of Restenosis After Coronary Stent ImplantationJournal of the American College of Cardiology, 1998
- Enhanced Endothelium-Dependent Relaxations After Gene Transfer of Recombinant Endothelial Nitric Oxide Synthase to Rabbit Carotid ArteriesHypertension, 1997
- Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5Science, 1997
- Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats.Journal of Clinical Investigation, 1996
- Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty.Journal of Clinical Investigation, 1995
- Cytostatic Gene Therapy for Vascular Proliferative Disorders with a Constitutively Active form of the Retinoblastoma Gene ProductScience, 1995